Gene:
P2RX1
purinergic receptor P2X, ligand-gated ion channel, 1

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  P2X1
PharmGKB Accession Id: PA32861

Details

Cytogenetic Location: chr17 : p13.3 - p13.2
GP mRNA Boundary: chr17 : 3799885 - 3819960
GP Gene Boundary: chr17 : 3796885 - 3829960
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Platelet Aggregation Inhibitor Pathway, Pharmacodynamics
    Effects of antiplatelet drugs on platelet aggregation pathway.

External Pathways

Links to non-PharmGKB pathways.

  1. Elevation of cytosolic Ca++ levels - (Reactome via Pathway Interaction Database)

Publications related to P2RX1: 2

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Blood gene expression correlated with tic severity in medicated and unmedicated patients with Tourette Syndrome. Pharmacogenomics. 2010. Liao Isaac H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood. 2009. Hartford Christine M, et al. PubMed

LinkOuts

Entrez Gene:
5023
OMIM:
600845
UCSC Genome Browser:
NM_002558
RefSeq RNA:
NM_002558
RefSeq Protein:
NP_002549
RefSeq DNA:
AC_000060
AC_000149
NC_000017
NG_012109
NT_010718
NW_001838403
NW_926584
UniProtKB:
P2RX1_HUMAN (P51575)
Ensembl:
ENSG00000108405
GenAtlas:
P2RX1
GeneCard:
P2RX1
MutDB:
P2RX1
ALFRED:
LO016596B
HuGE:
P2RX1
Comparative Toxicogenomics Database:
5023
HumanCyc Gene:
HS03099
IUPHAR Receptor:
P2X1 (478)
HGNC:
8533

Common Searches